Literature DB >> 32244983

High Risk of Sustained Ventricular Arrhythmia Recurrence After Acute Myocarditis.

Laurent Rosier1, Amir Zouaghi2, Valentin Barré3, Raphaël Martins3, Vincent Probst4, Eloi Marijon5, Nicolas Sadoul6, Samuel Chauveau7, Antoine Da Costa8, Marc Badoz9, Michael Peyrol10, Jérémie Barraud10, Grégoire Massoullie11, Romain Eschalier11, Madeline Espinosa12, François Lesaffre12, Rodrigue Garcia13, Bruno Degand13, Antoine Noël14, Jacques Mansourati14, Fabrice Extramiana15, Vincent Algalarrondo15, Hervé Devilliers16, Yves Cottin1,17, Estelle Gandjbakhch2, Charles Guenancia1,17.   

Abstract

Acute myocarditis is associated with cardiac arrhythmia in 25% of cases; a third of these arrhythmias are ventricular tachycardia (VT) or ventricular fibrillation (VF). The implantation of a cardiac defibrillator (ICD) following sustained ventricular arrhythmia remains controversial in these patients. We sought to assess the risk of major arrhythmic ventricular events (MAEs) over time in patients implanted with an ICD following sustained VT/VF in the acute phase of myocarditis compared to those implanted for VT/VF occurring on myocarditis sequelae. Our retrospective observational study included patients implanted with an ICD following VT/VF during acute myocarditis or VT/VF on myocarditis sequelae, from 2007 to 2017, in 15 French university hospitals. Over a median follow-up period of 3 years, MAE occurred in 11 (39%) patients of the acute myocarditis group and 24 (60%) patients of the myocarditis sequelae group. Kaplan-Meier MAE rate estimates at one and three years of follow-up were 19% and 45% in the acute group, and 43% and 64% in the sequelae group. Patients who experienced sustained ventricular arrhythmias during acute myocarditis had a very high risk of VT/VF recurrence during follow-up. These results show that the risk of MAE recurrence remains high after resolution of the acute episode.

Entities:  

Keywords:  implantable cardioverter defibrillator; myocarditis; ventricular fibrillation; ventricular tachycardia

Year:  2020        PMID: 32244983     DOI: 10.3390/jcm9030848

Source DB:  PubMed          Journal:  J Clin Med        ISSN: 2077-0383            Impact factor:   4.241


  5 in total

Review 1.  Viral Myocarditis: Classification, Diagnosis, and Clinical Implications.

Authors:  Fabiola B Sozzi; Elisa Gherbesi; Andrea Faggiano; Eleonora Gnan; Alessio Maruccio; Marco Schiavone; Laura Iacuzio; Stefano Carugo
Journal:  Front Cardiovasc Med       Date:  2022-06-20

2.  Fulminant Coxsackievirus Myocarditis in an Immunocompetent Adult: A Case Report and Literature Analysis.

Authors:  Ashish Jain; Rahul P Rane; Maha Mumtaz; Asfand Y Butt; Mahmoud Abdelsalam; Saba Waseem
Journal:  Cureus       Date:  2022-06-09

3.  Colchicine Is a Weapon for Managing the Heart Disease Among Interstitial Lung Disease With Viral Infection: Have We Found the Holy Grail?

Authors:  Jun-Jun Yeh; Tuey-Wen Hung; Cheng-Li Lin; Tsung-Tse Chen; Pei-Xuan Liw; Ya-Lun Yu; Chia-Hung Kao
Journal:  Front Cardiovasc Med       Date:  2022-06-28

4.  Acute Perimyocarditis Unmasking Anomalous Coronary Artery: Is Treating the Inflammation Enough? Does Surgery Fix All?

Authors:  Mariyam Sheidu; Xiaoxiao Qian; Hooman Bakhshi; Raghav Gattani; Araba Ofosu-Somuah; Abbas Reza Emaminia
Journal:  JACC Case Rep       Date:  2022-05-04

5.  Cardiovascular outcomes after cardiac resynchronization therapy in cardiac amyloidosis.

Authors:  Kilian Fischer; Nicolas Lellouche; Thibaud Damy; Raphaël Martins; Nicolas Clementy; Arnaud Bisson; François Lesaffre; Madeline Espinosa; Rodrigue Garcia; Bruno Degand; Guillaume Serzian; François Jourda; Olivier Huttin; Jean-Baptiste Guichard; Hervé Devilliers; Jean-Christophe Eicher; Gabriel Laurent; Charles Guenancia
Journal:  ESC Heart Fail       Date:  2021-11-03
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.